The results show no major reduction in the competition scenario in the US, a key market for most large drug companies. The sector saw decent earnings upgrades which sent the Nifty pharma index to a new high this week. Pharma companies impressed the Street in the September 2023 quarter, reporting a healthy expansion in revenues and earnings. Pricing environment improved in injectables and inhalers Pharma companies are focusing on high value and differentiated products Yet, most large companies managed to grow their revenues in US last quarter

Industry data indicate continuing price erosion in the US generic drug business